Adding Docetaxel to Androgen Deprivation Therapy in Patients With High-Risk Prostate Cancer

This randomized clinical trial compares the use of combined androgen-deprivation therapy plus docetaxel with androgen-deprivation therapy alone in patients with prostate cancer who develop increasing levels of prostate-specific antigen after primary local therapy.

http://bit.ly/2Gc1dkx